Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

Diabetes Research and Clinical Practice

Volumn 86, Issue SUPLL.1, 2009, Pages

  van Genugten, Renate E ^a   van Raalte, Daniël H ^a   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Exenatide; Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide (GIP); Incretin hormones; Type 2 diabetes mellitus (T2DM)

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ABDOMINAL DISTENSION; ABDOMINAL OBESITY; ACUTE PANCREATITIS; ADD ON THERAPY; ANTIBODY TITER; ARTICLE; BLOOD PRESSURE; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATTY LIVER; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; METABOLIC REGULATION; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET CELL HYPERPLASIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMACH EMPTYING; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN-SECRETING CELLS; PEPTIDES; PHENOTYPE; RECEPTORS, GLUCAGON; VENOMS;

EID: 72049120138     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(09)70006-3     Document Type: Article

References (51)

1. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46 1 (2003) 3-19
2. Turner R.C., Cull C.A., Frighi V., and Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49). JAMA 281 21 (1999) 2005-2012
3. Turner R.C., Cull C.A., Stratton I.M., Manley S.E., Kohner E.M., Matthews D.R., et al. UK Prospective Diabetes Study 16 - Overview of 6 Years Therapy of Type-II Diabetes: A Progressive Disease. Diabetes 44 11 (1995) 1249-1258
4. Wajchenberg B.L. Beta cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28 2 (2007) 187-218
5. Heine R.J., Diamant M., Mbanya J.C., and Nathan D.M. Management of hyperglycaemia in type 2 diabetes. BMJ 333 7580 (2006) 1200-1204A
6. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32 1 (2009) 193-203
7. Holman R.R., Paul S.K., Bethel M.A., Neil H.A., and Matthews D.R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359 (2008) 1565-1576
8. Drucker D.J. The biology of incretin hormones. Cell Metab 3 3 (2006) 153-165
9. Nauck M., Stockmann F., Ebert R., and Creutzfeldt W. Reduced incretin effect in type-2 (non-insulin-dependent) diabetes. Diabetologia 29 1 (1986) 46-52
10. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 6 (2007) 2131-2157
11. Doyle M.E., and Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113 3 (2007) 546-593
12. Buteau J., Roduit R., Susini S., and Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42 7 (1999) 856-864
13. Farilla L., Bulotta A., Hirshberg B., Li C.S., Khoury N., Noushmehr H., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 12 (2003) 5149-5158
14. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., and Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278 1 (2003) 471-478
15. Li Y., Cao X., Li L.X., Brubaker P.L., Edlund H., and Drucker D.J. Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54 2 (2005) 482-491
16. Wang X., Cahill C.M., Pineyro M.A., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 140 10 (1999) 4904-4907
17. Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87 3 (2002) 1239-1246
18. Holst J.J. The Physiology of glucagon-like peptide 1. Physiol Rev 87 (2007) 1409-1439
19. Balkan B., and Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279 4 (2000) R1449-R1454
20. Zheng D., Ionut V., Mooradian V., Stefanovski D., and Bergman R.N. Diabetes 58 (2009) 352 259
21. Qin X., Shen H., Liu M., Yang Q., Zheng S., Sabo M., et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipid production in rats. Am J Physiol Gastrointest Liver Physiol 288 (2005) G943-G949
22. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., and Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 3 (2001) 609-613
23. Rachman J., Barrow B.A., Levy J.C., and Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40 2 (1997) 205-211
24. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 7 (1999) 1137-1143
25. Todd J.F., Edwards C.M.B., Ghatei M.A., Mather H.M., and Bloom S.R. Subcutaneous glucagon-like peptide-I improves postprandial glycaemic control over a 3-week period in patients with early Type 2 diabetes. Clin Sci 95 3 (1998) 325-329
26. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 9309 (2002) 824-830
27. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 11 (2004) 2628-2635
28. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D.L., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 5 (2005) 1083-1091
29. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 5 (2005) 1092-1100
30. Buse J.B., Klonoff D.C., Nielsen L.L., Guan X.S., Bowlus C.L., Holcombe J.H., et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29 1 (2007) 139-153
31. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X.S., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opinion 24 1 (2008) 275-286
32. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., and Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial. Ann Intern Med 143 8 (2005) 559-569
33. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 29 11 (2007) 2333-2348
34. Bunck M.C., Diamant M., Corner A., Eliasson B., Malloy J.L., Shaginian R.M., et al. One-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: A randomized, controlled trial. Diabetes Care 32 5 (2009) 762-768
35. Bunck M.C., Corner A., Diamant M., Eliasson B., Malloy J.L., Shaginian R.M., et al. Exenatide improves postprandial hyperglycaemia and dyslipidaemia in metformin treated patients with type 2 diabetes. Diabetologia 51 (2008) S351 S351
36. Cervera A., Wajcberg E., Sriwijitkamol A., Fernandez M., Zuo P.G., Triplitt C., et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 294 5 (2008) E846-E852
37. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50 2 (2007) 259-267
38. Mari A., Nielsen L.L., Nanayakkara N., DeFronzo R.A., Ferrannini E., and Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 38 12 (2006) 838-844
39. UKPDS Study group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 9131 (1998) 837-853
40. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8 4 (2006) 436-447
41. Bunck M.C., Diamant M., Eliasson B., Corner A., Wu Y., Shaginian R.M., et al. Beneficial changes on body composition and circulating adiponectin and hsCRP levels following one-year exenatide therapy, compared with insulin glargine, in metformin-treated patients with type 2 diabetes. Diabetes 58 Suppl 1 (2009) A125
42. Stefan N., Kantartzis K., and Haring H.U. Causes and metabolic consequences of fatty liver. Endocr Rev 29 7 (2008) 939-960
43. Tushuizen M.E., Bunck M.C., Pouwels P.J., van Waesberghe J.H.T., Diamant M., and Heine R.J. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 26 8 (2006) 1015-1017
44. Ding X., Saxena N.K., Lin S., Gupta N.A., and Anania F.A. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43 1 (2006) 173-181
45. Bunck M.C., Corner A., Eliasson B., Wu Y., Shaginian R.M., Yan P., et al. One-year exenatide therapy, compared with insulin glargine, reduces postprandial oxidative stress in metformin-treated patients with type 2 diabetes. Diabetes 58 Suppl 1 (2009) A147 A147
46. Ahmad S.R., and Swann J. Exenatide and rare adverse events. N Engl J Med 358 18 (2008) 1970-1971
47. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriquez-Pattzi H., Olvera-Alvarez I., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009) 473-481
48. Matveyenko A.V., Dry S., Cox H.I., Moshtaghian A., Gurlo T., Galasso R., et al. Beneficial endocrine but adverse exocrine effectsofsitagliptininthehumanisletamyloidpolypeptide transgenic rat model of type 2 diabetes: Interactions with metformin. Diabetes 58 7 (2009) 1604-1615
49. http://www.reuters.com/article/pressRelease/idUS45457+06-Jun-2009+BW20090606
50. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients - Variations with increasing levels of HbA(1c). Diabetes Care 26 3 (2003) 881-885
51. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D.L., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372 9645 (2008) 1240-1250